PM359
Biologic
PM359 is one of 29 biologic programs targeting Chronic Granulomatous Disease. It is currently in development.
1
Indications
1
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
42 competitors in Chronic Granulomatous Disease
#DrugCompanyPhaseTrials
1Advil
KKenvue Brands
Approved
Interferon-Gamma
SSPP Pharmaclon Ltd.
Approved
Fludara
SanofiPhase 2
Neoral
NovartisPhase 2
Busulfex
Akero TherapeuticsPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Promacta
GSKPhase 2
Actemra
RochePhase 2
Sporanox
SSebela Pharmaceuticals Development LLC
Phase 2
Noxafil
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for PM359. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Company
- PPrime Medicine, Inc.